Skip to main content
Premium Trial:

Request an Annual Quote

Marligen Raises $2.3 Million

NEW YORK, May 10 (GenomeWeb News) - Marligen Biosciences said today that it has raised $2.3 million in funding through a Series A round of financing, as well as grants from government and non-profit agencies.

 

Among the company's investors in the financing round were Emerging Technology Partners and ASM Resources, Marligen said.

 

"We are delighted that our efforts to raise cash from several sources were successful," Marligen founder and CEO Sherry Challberg said in a statement. "In addition to completing our Series A financing, we also have been awarded a Maryland Department of Business & Economic Development Challenge grant, a MdBio Technology Accelerator Award, and a Phase II Small Business Innovation Research grant."

 

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.